Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.
Aspergillus flavus
Candida albicans
Otomycosis
Resistance
Tympanic membrane perforation
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
27
09
2020
accepted:
17
02
2021
pubmed:
16
3
2021
medline:
28
9
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Fungal otitis externa, an infection of the external auditory canal caused by molds and yeasts, accounts for approximately 10-20% of ear canal infections accompanying high recurrence. The purpose of the current study was to assess the pattern of etiological agents of otomycosis and resistance profile as well as the rate of tympanic membrane perforation. A total of 1040 patients with symptoms of fungal otitis externa, in a period of two years, were investigated. The mycological tests revealed the presence of different fungi in 237 ears (22.8%). Fungal otitis was more related to filamentous fungi of the species Aspergillus flavus (54.43%), A. tubingensis (10.97%), and A. niger (8.86%), followed by yeasts, Candida orthopsilosis (7.59%), C. albicans (6.75%), and C. parapsilosis (5.06%). Tympanic membrane perforation rate was found to be 6.75% and was more common with otomycosis caused by A. flavus, A. tubingensis and C. albicans. In antifungal susceptibility tests, all tested drugs showed generally good activity against most isolates of molds and yeasts, while tolnaftate, clotrimazole, nystatin, and terbinafine had lowest effects. We found that among Aspergillus isolates, one A. niger isolate was resistant to voriconazole, and one A. flavus isolate was resistant to amphotericin B. Furthermore, among Candida species, three isolates of C. orthopsilosis showed high MIC values to fluconazole, two C. albicans isolates were considered fluconazole resistant and one isolate of C. parapsilosis was resistant to caspofungin and 3 isolates were resistant to fluconazole. Regarding the existence of the cases with perforated tympanic membrane and emerging species causing fungal otitis in the current report, the importance of the early physical examination, precise molecular identification, and the antifungal susceptibility evaluation is highlighted.
Identifiants
pubmed: 33718990
doi: 10.1007/s11046-021-00537-1
pii: 10.1007/s11046-021-00537-1
doi:
Substances chimiques
Antifungal Agents
0
Amphotericin B
7XU7A7DROE
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-257Subventions
Organisme : Mazandaran University of Medical Sciences
ID : 1222
Références
Viswanatha B, Sumatha D, Vijayashree MS. Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review. Ear Nose Throat J. 2012;91(3):114–21.
pubmed: 22430336
doi: 10.1177/014556131209100308
Kurnatowski P, Filipiak A. Otomycosis: prevalence, clinical symptoms, therapeutic procedure. Mycoses. 2001;44(11–12):472–9.
pubmed: 11820260
doi: 10.1046/j.1439-0507.2001.00689.x
Koltsidopoulos P, Skoulakis C. Otomycosis with tympanic membrane perforation: a review of the literature. Ear Nose Throat J. 2019. https://doi.org/10.1177/0145561319851499 .
doi: 10.1177/0145561319851499
pubmed: 31142158
Rath S, Das SR, Padhy RN. Bayesian analysis of two methods MALDI-TOF-MS system and culture test in otomycosis infection. World J Otorhinolaryngol Head Neck Surg. 2019;5(1):6–13.
pubmed: 30775695
pmcid: 6364575
doi: 10.1016/j.wjorl.2018.03.006
Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Head Neck Surg. 2006;135(5):787–91.
pubmed: 17071313
doi: 10.1016/j.otohns.2006.07.008
Hagiwara S, Tamura T, Satoh K, et al. The molecular identification and antifungal susceptibilities of Aspergillus species causing otomycosis in Tochigi Japan. Mycopathologia. 2019;184(1):13–21.
pubmed: 30291485
doi: 10.1007/s11046-018-0299-9
Vennewald I, Klemm E. Otomycosis: diagnosis and treatment. Clin Dermatol. 2010;28(2):202–11.
pubmed: 20347664
doi: 10.1016/j.clindermatol.2009.12.003
pmcid: 20347664
Del Palacio A, Cuetara MS, López-Suso MJ, Amor E, Garau M. Randomized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis. Mycoses. 2002;45(7–8):317–28.
pubmed: 12572722
doi: 10.1046/j.1439-0507.2002.00737.x
Prasad SC, Kotigadde S, Shekhar M, et al. Primary otomycosis in the Indian subcontinent: predisposing factors, microbiology, and classification. Int J Microbiol. 2014;2014:1–9.
doi: 10.1155/2014/636493
Jia X, Liang Q, Chi F, Cao W. Otomycosis in shanghai: aetiology, clinical features and therapy. Mycoses. 2012;55(5):404–9.
pubmed: 21999222
doi: 10.1111/j.1439-0507.2011.02132.x
pmcid: 21999222
Ali K, Hamed MA, Hassan H, Esmail A, Sheneef A. Identification of fungal pathogens in otomycosis and their drug sensitivity: our experience. Int Arch Otorhinolaryngol. 2018;22(04):400–3.
pubmed: 30357045
pmcid: 6197964
doi: 10.1055/s-0038-1626702
Sarwestani ZK, Hashemi SJ, Rezaie S, et al. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. J Mycol Med. 2018;28(2):279–84.
doi: 10.1016/j.mycmed.2018.02.003
Szigeti G, Sedaghati E, Mahmoudabadi AZ, et al. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran. Mycoses. 2012;55(4):333–8.
pubmed: 21895787
doi: 10.1111/j.1439-0507.2011.02103.x
pmcid: 21895787
Aboutalebian S, Mahmoudi S, Mirhendi H, Okhovat A, Abtahi H, Chabavizadeh J. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents. J Med Microbiol. 2019;68(6):918–23.
pubmed: 31063125
doi: 10.1099/jmm.0.000985
pmcid: 31063125
Mofatteh MR, Yazdi ZN, Yousefi M, Namaei MH. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Braz J Otorhinolaryngol. 2018;84(4):404–9.
pubmed: 28549873
doi: 10.1016/j.bjorl.2017.04.004
pmcid: 28549873
Szigeti G, Kocsubé S, Dó czi I, Bereczki L, Vá gvö lgyi C, Varga J. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary. Mycopathologia. 2012;174:143–7.
pubmed: 22359155
doi: 10.1007/s11046-012-9529-8
pmcid: 22359155
Dundar R, İynen İ. Single dose topical application of clotrimazole for the treatment of otomycosis: is this enough? J Audiol Otol. 2019;23(1):15.
pubmed: 30518195
doi: 10.7874/jao.2018.00276
pmcid: 30518195
Kumar KR. Silent perforation of tympanic membrane and otomycosis. Indian J Otolaryngol. 1984;36(4):161–2.
Pradhan B, Tuladhar NR, Amatya RM. Prevalence of otomycosis in outpatient department of otolaryngology in Tribhuvan University Teaching Hospital, Kathmandu Nepal. Ann Otol Rhinol Laryngol. 2003;112(4):384–7.
pubmed: 12731637
doi: 10.1177/000348940311200416
pmcid: 12731637
Abou-halawa AS, Khan MA, Alrobaee AA, Alzolibani AA, Alshobaili HA. Otomycosis with perforated tympanic membrane: self medication with topical antifungal solution versus medicated ear wick. Int J Health Sci. 2012;6(1):73.
doi: 10.12816/0005975
Verweij PE, Howard SJ, Melchers WJG, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12(6):141–7.
pubmed: 19879181
doi: 10.1016/j.drup.2009.09.002
pmcid: 19879181
Balajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the transplant-associated infection surveillance network. J Clin Microbiol. 2009;47(10):3138–41.
pubmed: 19675215
pmcid: 2756904
doi: 10.1128/JCM.01070-09
Mushi MF, Buname G, Bader O, Groß U, Mshana SE. Aspergillus fumigatus carrying TR34/L98H resistance allele causing complicated suppurative otitis media in Tanzania: call for improved diagnosis of fungi in sub-Saharan Africa. BMC Infect Dis. 2016;16(1):464.
pubmed: 27589956
pmcid: 5009654
doi: 10.1186/s12879-016-1796-4
Nasri T, Hedayati MT, Abastabar M, et al. PCR-RFLP on β-tubulin gene for rapid identification of the most clinically important species of Aspergillus. J Microbiol Methods. 2015;117:144–7.
pubmed: 26264625
doi: 10.1016/j.mimet.2015.08.007
pmcid: 26264625
Didehdar M, Shokohi T, Khansarinejad B, et al. Characterization of clinically important dermatophytes in North of Iran using PCR-RFLP on ITS region. J Mycol Med. 2016;26(4):345–50.
pubmed: 27496524
doi: 10.1016/j.mycmed.2016.06.006
pmcid: 27496524
Falahati M, Ghojoghi A, Abastabar M, et al. The first case of total dystrophic onychomycosis caused by Aspergillus clavatus resistant to antifungal drugs. Mycopathologia. 2016;181(3–4):273–7.
pubmed: 26474550
doi: 10.1007/s11046-015-9954-6
pmcid: 26474550
Abastabar M, Hosseinpoor S, Hedayati MT, Shokohi T, Valadan R, Mirhendi H, Mohammadi R, Aghili SR, Rahimi N, Aslani N, Haghani I. Hyphal wall protein 1 gene: a potential marker for the identification of different Candida species and phylogenetic analysis. Curr Med Mycol. 2016;2(4):1.
pubmed: 28959789
pmcid: 5611690
doi: 10.18869/acadpub.cmm.2.4.1
Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol. 2013;51(6):657–63.
pubmed: 23470036
doi: 10.3109/13693786.2013.770603
pmcid: 23470036
Mirhendi H, Zarei F, Motamedi M, Nouripour-Sisakht S. Aspergillus tubingensis and Aspergillus niger as the dominant black Aspergillus, use of simple PCR-RFLP for preliminary differentiation. J Mycol Med. 2016;26(1):9–16.
pubmed: 26852194
doi: 10.1016/j.mycmed.2015.12.004
pmcid: 26852194
Clsi WPA. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard—third edition CLSI document M27-A3 Clinical and Laboratory Standard Institute. 2008.
Ghannoum M. M27-S4 Reference Method for Broth Dilution Antifungal susceptibility Testing of Yeast. In: Clinical and laboratory standards institute. Clinical and laboratory ; 2012.
Omran SM, Taghizadeh-Armaki M, Zarrinfar H, Hedayati MT, Abastabar M, Moqarabzadeh V, Ansari S, Saber S, Hoseinnejad A, Miri A, Verweij PE. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother. 2019;25(2):157–60.
pubmed: 30241879
doi: 10.1016/j.jiac.2018.07.018
pmcid: 30241879
Lass-Flörl C. Susceptibility testing in Aspergillus species complex. Clin Microbiol Infect. 2014;20:49–53.
pubmed: 24372722
doi: 10.1111/1469-0691.12514
Fasunla J, Ibekwe T, Onakoya P. Otomycosis in western Nigeria. Mycoses. 2008;51(1):67–70.
pubmed: 18076598
Yavo W, Kassi RR, Kiki-Barro PC, et al. Prevalence and risk factors for otomycosis treated in the hospital setting in Abidjan (Ivory Coast). Med Trop. 2004;64(1):39–42.
Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the north eastern part of Haryana. Int J Pediatr Otorhinolaryngol. 2010;74(6):604–7.
pubmed: 20347163
doi: 10.1016/j.ijporl.2010.03.001
Anwar K, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pakistan journal of medical sciences. 2014;30(3):564.
pubmed: 24948980
pmcid: 4048507
Hurst WB. Outcome of 22 cases of perforated tympanic membrane caused by otomycosis. J Laryngol Otol. 2001;115(11):879–80.
pubmed: 11779301
doi: 10.1258/0022215011909486
Gharaghani M, Seifi Z, Mahmoudabadi AZ. Otomycosis in Iran: a review. Mycopathologia. 2015;179(5–6):415–24.
pubmed: 25633436
doi: 10.1007/s11046-015-9864-7
Barati B, Okhovvat SAR, Goljanian A, Omrani MR. Otomycosis in central Iran: a clinical and mycological study. Iran Red Crescent Med J. 2011;13(12):873.
pubmed: 22737432
pmcid: 3371907
Suraneni VR, Kapilavaya N, Rayapu SB, Kudamala S. Clinical and microbiological Study of Otomycosis. J Evid Based Med Healthc. 2017;4(51):3098–102.
doi: 10.18410/jebmh/2017/615
Li Y, He L. Diagnosis and treatment of otomycosis in southern China. Mycoses. 2019;62(11):1064–8.
pubmed: 31368588
doi: 10.1111/myc.12979
pmcid: 31368588
Pontes ZBVdS, Silva ADF, Lima EdO, et al. Otomycosis: a retrospective study. Braz J Otorhinolaryngol. 2009;75(3):367–70.
pubmed: 19649486
doi: 10.1590/S1808-86942009000300010
pmcid: 19649486
Agarwal P, Devi LS. Otomycosis in a rural community attending a tertiary care hospital: assessment of risk factors and identification of fungal and bacterial agents. J Clin Diagn Res: JCDR. 2017;11(6):DC14.
Yehia MM, Al-Habib HM, Shehab NM. Otomycosis: a common problem in north Iraq. J Laryngol Otol. 1990;104(5):387–9.
pubmed: 2370463
doi: 10.1017/S0022215100158529
pmcid: 2370463
Paulose KO, Al Khalifa S, Shenoy P, Sharma RK. Mycotic infection of the ear (otomycosis): a prospective study. J Laryngol Otol. 1989;103(1):30–5.
pubmed: 2921549
doi: 10.1017/S0022215100107960
pmcid: 2921549
Nemati S, Hassanzadeh R, Jahromi SK, Abadi ADN. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Arch Otorhinolaryngol. 2014;271(5):953–7.
pubmed: 23595615
doi: 10.1007/s00405-013-2486-0
pmcid: 23595615
Kiakojuri K, Rajabnia R, Jalili B, Khafri S, Omran SM. Otomycosis in adolescent patients referred to the therapeutic centers in Babol City, Iran. Jundishapur J Microbiol. 2015;8(5).
Yegane MA, Asadi MA, Dehghani RA, Houshyar H. The prevalence of otomycosis in Kashan, Iran, during 2001–2003. Jundishapur J Microbiol. 2009;2(1):18–21.
Fayemiwo SA, Ogunleye VO, Adeosun AA, Bakare RA. Prevalence of otomycosis in Ibadan: a review of laboratory reports. Afr J Med Med Sci. 2010;39:219–22.
pubmed: 22420052
pmcid: 22420052
Garcia-Martos P, Delgado D, Marin P, Mira J. Analysis of 40 cases of otomycosis. Enferm Infecc Microbiol Clin. 1993;11(9):487.
pubmed: 8305556
pmcid: 8305556
García-Agudo L, Aznar-Marín P, Galán-Sánchez F, García-Martos P, Marín-Casanova P, Rodríguez-Iglesias M. Otomycosis due to filamentous fungi. Mycopathologia. 2011;172(4):307.
pubmed: 21499908
doi: 10.1007/s11046-011-9427-5
pmcid: 21499908
Değerli K, Ecemiş T, Günhan K, Başkesen T, Kal E. Agents of otomycosis in Manisa region, Turkey, 1995–2011. Mikrobiyol Bul. 2012;46(1):79–84.
pubmed: 22399174
pmcid: 22399174
Ozcan KM, Ozcan M, Karaarslan A, Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy. J Laryngol Otol. 2003;117(1):39–42.
pubmed: 12590854
doi: 10.1258/002221503321046621
pmcid: 12590854
Zarei F, Mirhendi H, Motamedi M, et al. Black Aspergillus species isolated from clinical and environmental samples in Iran. J Med Microbiol. 2015;64(11):1454–6.
pubmed: 26384733
doi: 10.1099/jmm.0.000166
pmcid: 26384733
Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology. 2007;153(6):1677–92.
pubmed: 17526826
doi: 10.1099/mic.0.2007/007641-0
pmcid: 17526826
Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol. 2008;72(4):453–9.
pubmed: 18279975
doi: 10.1016/j.ijporl.2007.12.005
pmcid: 18279975
Ahmed MR, Abou-Halawa AS, Hessam WF, Abdelkader DSA. A search for new otomycotic species and their sensitivity to different antifungals. Interv Med Appl Sci. 2018;10(3):145–9.
pubmed: 30713753
pmcid: 6343575
Araiza J, Canseco P, Bonifaz A. Otomycosis: clinical and mycological study of 97 cases. Rev Laryngol Otol Rhinol. 2006;127(4):251–4.
Panchal P, Pethani J, Patel D, Rathod S, Shah P. Analysis of various fungal agents in clinically suspected cases of otomycosis. Indian J Basic Appl Med Res. 2013;2(08):12–9.
Omran SM, Taghizadeh-Armaki M, Zarrinfar H, et al. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother. 2019;25(2):157–60.
pubmed: 30241879
doi: 10.1016/j.jiac.2018.07.018
pmcid: 30241879
Karaarslan A, Arikan S, Ozcan M, Ozcan KM. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis. Mycoses. 2004;47(7):284–7.
pubmed: 15310330
doi: 10.1111/j.1439-0507.2004.00988.x
pmcid: 15310330
Abastabar M, Rahimi N, Meis JF, et al. Potent activities of novel imidazoles lanoconazole and luliconazole against a collection of azole-resistant and-susceptible Aspergillus fumigatus strains. Antimicrob Agents Chemother. 2016;60(11):6916–9.
pubmed: 27572389
pmcid: 5075107
doi: 10.1128/AAC.01193-16
Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, Tamura T, Satoh K, Abastabar M, Shokoohi GR, Ahmadi B, Kord M, Taghipour S, Makimura K. In vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. Antimicrobial agents and chemotherapy, 2018;1:62(5)
Abastabar M, Al-Hatmi AM, Moghaddam MV, De Hoog GS, Haghani I, Aghili SR, Shokohi T, Hedayati MT, Ghazvini RD, Kachuei R, Rezaei-Matehkolaei A. Potent activities of luliconazole, lanoconazole, and eight comparators against molecularly characterized Fusarium species. Antimicrobial agents and chemotherapy. 2018;1:62(5).
Hadrich I, Makni F, Neji S, Cheikhrouhou F, Bellaaj H, Elloumi M, Ayadi A, Ranque S. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol. 2012;50(8):829–34.
pubmed: 22587728
doi: 10.3109/13693786.2012.684154
pmcid: 22587728
Gharaghani M, Halvaeizadeh M, Jalaee GA, Taghipoor S, Kiasat N, Zarei MA. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz Iran. Curr Med Mycol. 2020;6(2):18–22.
pubmed: 33628977
pmcid: 7888522
Badali H, Fakhim H, Zarei F, et al. In vitro activities of five antifungal drugs against opportunistic agents of Aspergillus Nigri complex. Mycopathologia. 2016;181(3–4):235–40.
pubmed: 26615417
doi: 10.1007/s11046-015-9968-0
pmcid: 26615417
Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 1988;32(5):780–1.
pubmed: 3134851
pmcid: 172275
doi: 10.1128/AAC.32.5.780
Nong H, Li J, Huang G, Nong D, Cheng P, Yao C. The observation of mycology and clinical efficacy in 325 cases with otomycosis. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1999;13(10):438–40.
pubmed: 12541393
Mahmoudabadi AZ, Seifi Z, Gharaghani M. Lamisil, a potent alternative antifungal drug for otomycosis. Curr Med Mycol. 2015;1(1):18.
doi: 10.18869/acadpub.cmm.1.1.18
Yang T-H, Young Y-H. Eradicating otomycosis with terbinafine solution: basic and clinical investigation. Audiol Neurootol. 2019;24(4):183–90.
pubmed: 31454819
doi: 10.1159/000501540
Abastabar M, Haghani I, Ahangarkani F, Rezai MS, Taghizadeh Armaki M, Roodgari S, Kiakojuri K, Al-Hatmi AM, Meis JF, Badali H. Candida auris otomycosis in Iran and review of recent literature. Mycoses. 2019;62(2):101–5.
pubmed: 30585653
doi: 10.1111/myc.12886
Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25(9):1780.
pubmed: 31310230
pmcid: 6711235
doi: 10.3201/eid2509.190686